Tianjin Pharmaceutical da Ren Tang Group Ltd 2023 AR2
The report highlights Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's financial and operational performance for the fiscal year 2023. The company achieved a record operating income of RMB 8.222 billion and a net profit of RMB 987 million, representing a 14.49% year-on-year increase. Key achievements include the expansion of its 'three cores and nine wings' product strategy, with Suxiao Jiuxin Wan sales exceeding RMB 2 billion for the first time. Additionally, the company advanced its green traditional Chinese medicine initiatives, established a whole-process quality traceability system, and prepared for the publication of its standalone 2023 Sustainability Report.
Company: Tianjin Pharmaceutical da Ren Tang Group Ltd
Sector: Manufacturing
Country: China
Year: 2023
Type: AR2
Pages: 204
Back to company
Tianjin Pharmaceutical da Ren Tang Group Ltd
Annual Report
The report highlights Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's financial and operational performance for the fiscal year 2023. The company achieved a record operating income of RMB 8.222 billion and a net profit of RMB 987 million, representing a 14.49% year-on-year increase. Key achievements include the expansion of its 'three cores and nine wings' product strategy, with Suxiao Jiuxin Wan sales exceeding RMB 2 billion for the first time. Additionally, the company advanced its green traditional Chinese medicine initiatives, established a whole-process quality traceability system, and prepared for the publication of its standalone 2023 Sustainability Report.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jan 1, 2023 - Dec 31, 2023
Fiscal Year
2023
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
No data available